Market Overview

Lexicon Shares Fall 47% On Termination Of License Agreement With Sanofi

Share:

Lexicon Pharmaceuticals (NASDAQ: LXRX) shares plummeted after the company received a written notice from Sanofi (NASDAQ: SNY) terminating the agreement for the development and commercialization of the company's Diabetes drug candidate Sotagliflozin.

Lexicon Pharmaceuticals shares were trading were trading down 47.45% at $2.99 in Monday’s pre-market session. The stock has a 52-week high of $12.95 and a 52-week low of $4.25.

Sanofi shares were trading up 2.34% at $43.35 in Monday’s pre-market session. The stock has a 52-week high of $45.62 and a 52-week low of $40.19.

Related Links:

Sanofi, Google Partner On Health Care-Focused Virtual Innovation Lab

Valeritas Insulin Device For Diabetics Accepted Under Managed Formulary

Posted-In: M&A News Movers Trading Ideas

 

Related Articles (LXRX + SNY)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Booz Allen Hamilton Reports Q1 Earnings Beat, Reaffirms Guidance

Exact Sciences Will Acquire Genomic Health In $2.8B Deal